ClinicalTrials.gg
TerminatedNCT05621213VNI_SLAUpdated Feb 6, 2026

Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation

An interventional study of Teleconsultation assisted by a physiotherapist or nurse in ALS and Charcot Disease, sponsored by AGIR à Dom. Terminated at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by AGIR à Dom · Not applicable, Interventional, and Health services research

How we know

Why this study was terminated
The study was terminated early due to insufficient recruitment despite mitigation measures, as enrolment rates could not meet protocol objectives. Academic thesis scheduling constraints also contributed. No safety concerns were identified.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Amyotrophic Lateral Sclerosis with a site in France — 28 open to participants now, 36 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · France.

Enrollment
68th of 103
38 · median 83
Started
2023
with 10 others
No phase
47 of 132
14 open now
Registered
100th of 132
by date

Among the 132 studies in Amyotrophic Lateral Sclerosis with a site in France, this one is the 68th largest by enrollment of the 103 interventional ones that give a count, is one of 11 that started in 2023, is one of 47 with no phase, and was the 100th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

28 of the 132 studies in Amyotrophic Lateral Sclerosis with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Amyotrophic Lateral Sclerosis with a site in France, or all of them as a file.
02

Study summary

Satisfaction of patients with amyotrophic lateral sclerosis under non-invasive ventilation regarding home assisted teleconsultation

Read the detailed description

Amyotrophic Lateral Sclerosis (ALS) is a progressive and rapidly progressing neurodegenerative disease. Depending on the degree of muscle damage, patients may suffer from reduced mobility, difficulty swallowing, speech difficulties and finally respiratory weakness. Death occurs within an average of 2-3 years and is usually due to respiratory failure. Currently there is no cure for ALS, so palliative care and symptomatic treatments are essential for the management of these patients.

The gold standard treatment for respiratory impairment is non-invasive ventilation (NIV). The aim of this mask ventilation is to improve gas exchange by compensating for the weakness of the respiratory muscles.

The progressive nature of ALS requires regular assessment of the patient's clinical condition and evaluation of NIV parameters. Regular medical appointments are therefore essential to ensure optimal ventilation and close surveillance of the patient. A day hospitalization or a consultation is organized every 3 or 4 months. These visits can cause significant fatigue, not only because of the difficulty patients have to move around but also because of the time spent waiting in hospital.

ALS is characterised by its severity and it requires our society to think about and implement new ways of managing the disease. Thus, e-health innovations could be an interesting potential in the remote follow-up of these patients, to reduce the burden of hospital consultations.

The hypothesis is that the patient will be more satisfied with a home assisted teleconsultation follow-up, while keeping the same quality of non-invasive nocturnal ventilatory assistance.

03

Conditions studied

  • ALS
  • Charcot Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a diagnosis of ALS coming for a follow-up consultation with their pneumologist
  • Daily NIV compliance of more than 4 hours in the month prior to inclusion
  • Living at home
  • Patient with a natural caregiver
  • Patient equipped with computer equipment adapted for teleconsultation (tablet, computer, telephone... with an internet connection)
  • Patient able to read and understand the procedure, and able to express consent for the study protocol
  • Patient, or his or her caregiver, able to sign the consent to participate by himself or herself

Exclusion criteria

Exclusion Criteria:

  • Patient not available or wishing to change region within 3 months of inclusion
  • Patient currently participating or having participated in the month prior to inclusion in another clinical interventional research study that may have an impact on the study, this impact is left to the discretion of the investigator
  • Persons referred to in articles L1121-5 to L1121-8 of the French Public Health Code (corresponding to all protected persons)
  • Pregnant women (for women of childbearing age and in the absence of reliable , the β-HCG (human chorionic gonadotropin) assay will be performed), parturient women, breastfeeding women,
  • persons deprived of their liberty by judicial or administrative decision,
  • persons under legal protection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Intervention

    Patients who will be followed up by teleconsultation assisted by a physiotherapist or a nurse at home.

    Other: Teleconsultation assisted by a physiotherapist or nurse

  • No intervention
    Control group

    Patients not wishing to be followed up by teleconsultation but agreeing to participate in the study and the collection of questionnaires. They will follow up as usual in person (no teleconsultation).

Interventions

  • OtherTeleconsultation assisted by a physiotherapist or nurse

    A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions. This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver.

06

What researchers measure

Primary outcomes

  1. Satisfaction of ALS patients followed by teleconsultation at home

    Evolution of the overall satisfaction score obtained from the Client Satisfaction Questionnaire CSQ-8, with 8 items, score 8-32. The higher the score, the more satisfied the patient is.

    Time frame: Between the initial visit and the 3-month visit

Secondary outcomes

  1. Evolution of the patient's physical functions

    Change in ALS-FRS-R (Amyotrophic lateral sclerosis functional rating scale revised) questionnaire score, score 0-48. The higher the score, the better the patient's physical function.

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  2. Non-inferiority of ventilatory efficiency compared to conventional management

    Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by S3-NIV (symptoms, sleep quality and side-effects related to the non-invasiv ventilation) questionnaire score 0-10. the higher the score, the fewer ALS-related symptoms the patient has.

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  3. Non-inferiority of ventilatory efficiency compared to conventional management

    Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by mean nocturnal oxygen saturation (SpO2, %) measured by oximetry

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  4. Non-inferiority of ventilatory efficiency compared to conventional management

    Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by time spent (in minutes) below 90% SpO2, measured by oximetry

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  5. Non-inferiority of ventilatory efficiency compared to conventional management

    Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by mean PtCO2 (in mmHg), measured by capnography

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  6. Non-inferiority of ventilatory efficiency compared to conventional management

    Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by time spent (in minutes) above 50 mmHg PtCO2 measured by capnography

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  7. Non-inferiority of ventilatory efficiency compared to conventional management

    Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine.

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  8. Non-inferiority of ventilatory efficiency compared to conventional management

    Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the unintentional leakage through telemonitoring of the data recorded by the CPAP machine.

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  9. Non-inferiority of ventilatory efficiency compared to conventional management

    Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the residual Apnea-Hypopnea Index (AHI) through telemonitoring of the data recorded by the CPAP machine.

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  10. The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit

    Comparison of the evolution of ventilation efficiency assessed from clinical parameters measured by S3-NIV (symptoms, sleep quality and side-effects related to the non-invasiv ventilation) questionnaire, score 0-10. the higher the score, the fewer ALS-related symptoms the patient has.

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  11. The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit

    Comparison of the evolution of ventilation efficiency assessed from mean PtCO2 (in mmHg), measured by capnography

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  12. The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit

    Comparison of the evolution of ventilation efficiency assessed from time spent (in minutes) below 90% SpO2, measured by oximetry

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  13. The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit

    Comparison of the evolution of ventilation efficiency assessed from mean nocturnal oxygen saturation (SpO2,%) measured by oximetry

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  14. The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit

    Comparison of the evolution of ventilation efficiency assessed from time spent (in minutes) above 50 mmHg PtCO2 measured by capnography

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  15. The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit

    Comparison of the evolution of ventilation efficiency assessed by the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine.

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  16. The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit

    Comparison of the evolution of ventilation efficiency assessed by the unintentional leakage through telemonitoring of the data recorded by the CPAP machine.

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  17. The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit

    Comparison of the evolution of ventilation efficiency assessed by the residual Apnea-Hypopnea Index (AHI) through telemonitoring of the data recorded by the CPAP machine.

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  18. Patient satisfaction with teleconsultation itself (use and patient/doctor interaction)

    Evaluation of the score of the Visit Satisfaction Questionnaire (VSQ-VF) score 0-100. The higher the score, the more satisfied the patient is.

    Time frame: After each teleconsultation (3-month visit and 6-month visit)

  19. The evolution of satisfaction between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit

    Comparison of the variation in the score of the visit satisfaction questionnaire, assessed by the VSQ-VF questionnaire, score 0-100. The higher the score, the more satisfied the patient is.

    Time frame: Between the 3-month visit, and the 6-months visit

  20. Physician satisfaction with teleconsultation

    Evaluation made by Visual Analogue Scale (VAS) from 0 to 10 cm. The higher the score, the more satisfied the physician is.

    Time frame: After each teleconsultation (3-month visit and 6-month visit)

  21. Caregivers' satisfaction with the care of the relative

    Change in caregiver satisfaction measured with client satisfaction questionnaire score (CSQ-8 modified) with 8 items, score 8-32. The higher the score, the more satisfied the caregivers' is.

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  22. The feasibility of home teleconsultation for ALS patients

    Number of failed teleconsultations requiring rescheduling

    Time frame: Between the initial visit, the 3-month visit, and the 6-months visit

  23. Retention of follow-up modality

    Number of patients who changed follow-up modality, assessed by the number of face-to-face follow-up

    Time frame: At 6 months

07

Study locations

2 sites
  • CHU Grenoble Alpes
    Grenoble, France 38043, France
  • CHU Montpellier
    Montpellier, France 34295, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Dec 2024, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2022
First posted
Nov 17, 2022
StartActual
Jan 13, 2023
Primary completionActual
Dec 31, 2024
CompletionActual
Sep 5, 2025
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05621213
Lead sponsor
AGIR à Dom
Responsible party
Sponsor
First posted
Nov 17, 2022
Start date
Jan 13, 2023
Primary completion
Dec 31, 2024
Completion
Sep 5, 2025
Last update
Feb 6, 2026

Study contacts

Christel Saint-Raymond, PhD
principal investigator · CHU Grenoble Alpes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion